Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly called Polycystic Ovary Syndrome (PCOS), is both a reproductive and metabolic condition. The diabetes connection is important because glucose dysregulation can develop even when fasting glucose, A1C, or body weight initially appears reassuring.
The most useful question is not whether one insulin or testosterone result looks “high.” It is whether glucose regulation is impaired, whether cardiometabolic risk is increasing, and whether testing is sensitive enough to detect early abnormalities.
Current international PMOS guidance recommends the 75-g oral glucose tolerance test (OGTT) as the most accurate available test for assessing glycemic status in PMOS, regardless of BMI. A fasting plasma glucose or A1C can be considered when an OGTT cannot be performed, but both have reduced accuracy in this population.
That is why a person with PMOS can have a normal A1C and still have abnormal glucose handling after a glucose challenge.
This page intentionally has a narrow metabolic purpose. It does not repeat the full PMOS diagnostic work-up, menstrual criteria, AMH guidance, androgen differential diagnosis, or fertility evaluation.
For those subjects, use the canonical guide: PMOS (Formerly PCOS): Why Testosterone, Menstrual Patterns, Glucose Testing, and Metabolic Risk Must Be Read Together.
For broader testing education, use:
Insulin resistance is an important biological feature of PMOS. When tissues become less responsive to insulin, the pancreas may need to release more insulin to maintain glucose control. Over time, some people lose the ability to keep glucose within a healthy range, leading to impaired fasting glucose, impaired glucose tolerance, prediabetes, or type 2 diabetes.
Body weight can amplify metabolic risk, but it does not define it. International guidance states that women with PMOS have an increased risk of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes regardless of age and BMI.
This is a major reason the metabolic part of PMOS should not be postponed until fertility treatment, weight gain, or overt diabetes appears.
Hemoglobin A1C estimates average glucose exposure over roughly the previous two to three months. It is convenient and valuable, but an average can hide excursions.
A person may have:
That post-challenge abnormality is exactly what the Glucose Tolerance Test, 2 Specimens, 75g is designed to detect.
A1C can also be influenced by conditions that change red-blood-cell turnover or hemoglobin biology, including iron deficiency, anemia, some kidney conditions, pregnancy, and hemoglobin variants. These issues are not unique to PMOS, but they reinforce why no glycemic marker should be interpreted without context.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Glucose Tolerance Test, 2 Specimens, 75g — fasting and post-challenge glucose | Guideline-preferred assessment of glycemic status in PMOS; can reveal impaired glucose tolerance that fasting glucose or A1C misses. | Requires specific preparation, fasting, a measured glucose drink, and timed collection. Acute illness, medication effects, and preparation errors can affect results. |
| Glucose Test — commonly used as fasting plasma glucose when ordered fasting | Provides a convenient snapshot of glucose regulation and can identify fasting hyperglycemia. | A normal fasting result can miss abnormal post-challenge glucose. Recent food intake, illness, stress, medications, and collection conditions can influence the result. |
| Hemoglobin A1C Test — longer-term glucose exposure | Useful for diabetes and prediabetes assessment and longitudinal monitoring; may be used when OGTT is not feasible. | Reduced accuracy compared with OGTT for PMOS-specific glycemic assessment. Anemia, iron deficiency, kidney disease, pregnancy, hemoglobin variants, and altered red-cell turnover may affect interpretation. |
For PMOS, the third question can reveal a metabolic problem that the first two do not capture.
Because insulin resistance is closely associated with PMOS, many patients are drawn to Fasting Insulin, insulin/glucose ratios, or HOMA-IR.
These measurements can be interesting in selected clinical or research contexts, but the international PMOS guideline states that currently available insulin assays have limited clinical relevance and are not recommended for routine PMOS care.
There is no universally accepted fasting-insulin or HOMA-IR cutoff that independently diagnoses PMOS, proves clinically meaningful insulin resistance, or determines treatment for every patient.
This does not mean insulin biology is unimportant. It means routine risk assessment should prioritize validated outcomes:
The older version of this article gave testosterone, SHBG, DHEA-S, and other reproductive hormones too much weight as diabetes-monitoring tools.
Those tests answer a different question.
Total Testosterone, Free Testosterone, SHBG, and DHEA-S can help characterize androgen excess in the broader PMOS evaluation. They do not diagnose prediabetes or diabetes and should not be serially tracked as a proxy for glucose improvement.
For the full androgen and menstrual diagnostic pathway, use the canonical PMOS guide.
International guidance recommends assessing glycemic status at diagnosis in adults and adolescents with PMOS, regardless of age or BMI.
It also recommends reassessing glycemic status approximately every one to three years, with the interval based on additional individual diabetes risk factors.
Earlier reassessment may be reasonable when there is:
The important concept is risk-based longitudinal testing, not a universal schedule for every person.
PMOS is associated with increased pregnancy-related metabolic risk. Current guidance recommends a 75-g OGTT in women with PMOS who are planning pregnancy or seeking fertility treatment and who do not already have diabetes.
If an OGTT was not completed before conception, the guideline supports testing at the first prenatal visit and again at 24–28 weeks.
Pregnancy also changes how glucose results, medications, weight-management therapy, metformin, fertility treatments, and other interventions should be handled. These decisions require clinician-directed care.
Dysglycemia is only one part of PMOS metabolic risk. Current guidance recommends a Lipid Panel at diagnosis regardless of age or BMI. The panel typically provides total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.
Patterns such as high triglycerides and low HDL can add evidence of cardiometabolic strain, but they do not diagnose diabetes.
Blood pressure should be checked regularly. A laboratory test cannot diagnose hypertension, so home or clinical measurements remain necessary.
A practical metabolic baseline may include:
PMOS can coexist with metabolic dysfunction–associated steatotic liver disease. ALT, AST, glucose, triglycerides, and body-composition trends can sometimes form a broader metabolic pattern.
Elevated liver enzymes do not prove that PMOS caused liver disease, and normal enzymes do not rule out significant liver disease. Persistent abnormalities should be evaluated as a separate liver-health question.
This is exactly why OGTT matters in PMOS. Average and fasting glucose can appear reassuring while post-challenge glucose is abnormal. The metabolic plan should follow the demonstrated dysglycemia rather than dismissing risk because A1C is normal.
A normal A1C does not eliminate risk. The guideline-preferred OGTT may be more informative, and glycemic reassessment should be individualized according to the change in risk profile.
This pattern suggests worsening cardiometabolic health rather than an isolated reproductive-hormone issue. Repeat glucose and lipid testing, blood-pressure assessment, and clinician-directed risk management become more important than repeating testosterone.
This may point toward a broader metabolic phenotype that includes dysglycemia and possible steatotic liver disease. Liver evaluation and cardiometabolic management should proceed as their own clinical questions.
This is a meaningful multisystem response. Improvement in glucose and lipid outcomes is generally more actionable for metabolic risk than a small change in testosterone, SHBG, or AMH.
Retest the marker that defined the metabolic problem or that is expected to change with intervention.
Examples:
Do not use repeated testosterone, DHEA-S, SHBG, or AMH measurements as a substitute for following glucose and cardiometabolic outcomes.
PMOS-specific metabolic screening and established diabetes management are not the same thing.
Once someone has diagnosed diabetes, the monitoring plan expands to diabetes-specific complication prevention and treatment. Depending on the individual, this may include kidney function, urine albumin, lipids, liver health, eye care, blood pressure, medication monitoring, and other testing.
Use the Diabetes and Prediabetes Blood Tests pillar for the broader diabetes pathway rather than turning the PMOS article into a duplicate diabetes-management guide.
Ulta Lab Tests provides direct online access, where available, to many of the glycemic, lipid, metabolic, and hormone tests discussed in this article.
For PMOS-related diabetes risk, the most useful direct-access strategy is to start with a defined question:
Use Direct-Access Lab Testing: How It Works and What to Expect for ordering, preparation, and collection information, and How to Read and Understand Your Lab Results for reference ranges, trends, and interpretation limits.
Direct-access testing does not replace diagnosis, diabetes treatment, medication management, pregnancy care, or urgent medical evaluation.
No. PMOS increases the risk of impaired glucose tolerance and type 2 diabetes, but progression is not inevitable. Individual risk depends on genetics, prior glycemic status, pregnancy history, body composition, lifestyle, medications, age, and other factors.
Current international PMOS guidance identifies the 75-g Oral Glucose Tolerance Test as the most accurate available test for glycemic status in PMOS, regardless of BMI.
Yes. A1C reflects average glucose exposure and can miss abnormal post-challenge glucose. An OGTT directly measures the glucose response to a standardized glucose drink.
Not routinely as a guideline-based PMOS outcome. Available insulin assays have limited clinical relevance for routine PMOS care. Follow validated glycemic measures and the specific abnormality that needs monitoring.
No. HOMA-IR is a calculated estimate derived from fasting glucose and insulin. It does not independently diagnose PMOS or replace established tests for prediabetes and diabetes.
No. SHBG can be influenced by insulin exposure, estrogen, thyroid status, liver function, body composition, and other factors. It is not a diabetes diagnostic test.
PMOS guidance recommends glycemic assessment regardless of BMI and identifies the 75-g OGTT as the most accurate test for glycemic status in PMOS. Body size alone should not determine whether metabolic risk is evaluated.
Guidance recommends reassessment about every one to three years depending on additional diabetes risk, with earlier testing when risk changes or pregnancy is planned.
For women with PMOS who do not already have diabetes, current guidance recommends an OGTT when planning pregnancy or seeking fertility treatment. If it was not completed before conception, testing should be addressed early in prenatal care and again at 24–28 weeks.
PMOS and diabetes connection: PMOS, formerly PCOS, increases the risk of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes, including in women who are not overweight.
Best glycemic test: The 75-g oral glucose tolerance test is the guideline-preferred and most accurate available test for assessing glycemic status in PMOS. A1C and fasting glucose may be used when OGTT is not feasible but can miss dysglycemia.
Normal A1C does not eliminate risk: A person can have a normal A1C and fasting glucose yet show an abnormal two-hour glucose response during an OGTT.
Fasting insulin limitation: Routine fasting insulin and HOMA-IR are not recommended as replacements for validated glycemic testing in PMOS because available insulin assays and cutoffs lack sufficient standardization for routine care.
Monitoring: Assess glycemic status when PMOS is diagnosed and generally repeat testing every one to three years based on individual risk. Follow abnormal glucose, lipid, liver, and blood-pressure patterns rather than using serial androgen measurements as metabolic-treatment scores.
Medical disclaimer: Laboratory testing provides health information but does not independently diagnose PMOS, prediabetes, or diabetes and does not replace medical advice, medication management, pregnancy care, or urgent evaluation. Review abnormal or changing results with a qualified healthcare professional.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
